Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 9Terminated 3Unknown 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 23Myeloid 17Sarcoma 9Gastrointestinal 7Lymphoid 6Tumor-Agnostic 2Other solid neoplasm 2Dermatologic 2Thoracic 1Head & Neck 1CNS 1

Conditions

Melanoma 2

Interventions

Nivolumab 27pembrolizumab 22Ipilimumab 17Temozolomide 13toripalimab 12Biopsy 10Cyclophosphamide 9Imiquimod 8Dacarbazine 7Blood Specimen Collection 7camrelizumab 6Chemotherapy, Adjuvant 6trametinib 5fludarabine 5dabrafenib 5atezolizumab 5aldesleukin 5Gene Expression Profiling 5Cisplatin 5Aminolevulinic Acid 5fludarabine phosphate 4durvalumab 4binimetinib 4apatinib 4Tomography, Optical Coherence 4Sorafenib 4Photochemotherapy 4Interleukin-2 4Injections 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Imatinib Mesylate × Dermatologic × Clear all
NCT04546074 2023-10-03

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

Keio University

Phase 1/2 Unknown
22 enrolled
Dermatologic

Melanoma

NCT01782508 2013-02-04

A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma

Peking University Cancer Hospital & Institute

Phase 2 Unknown
40 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡